Rocket Pharmaceuticals, Inc. RCKT

RCKT Company Overview

Rocket Pharmaceuticals, Inc. is a U.S.-based biotechnology company focused on developing and commercializing gene therapies for rare and devastating diseases. The company operates primarily in the biotechnology and genetic medicine industries, with a concentration on therapies targeting inherited cardiovascular disorders, hematologic diseases, and immunologic conditions. Rocket’s development platform includes both lentiviral (LV) gene therapy and adeno-associated virus (AAV) gene therapy technologies, which are designed to address diseases caused by single-gene mutations.

The company’s primary value drivers are its clinical-stage gene therapy programs, intellectual property portfolio, regulatory designations, and manufacturing capabilities. Rocket has emphasized rare pediatric and orphan diseases where there are limited or no approved treatment options. Its strategic positioning is supported by in-house clinical development expertise, proprietary viral vector manufacturing infrastructure, and multiple programs that have received orphan drug, rare pediatric disease, regenerative medicine advanced therapy (RMAT), or fast track designations from the U.S. Food and Drug Administration. Rocket Pharmaceuticals was founded in 1999 and later evolved into a focused gene therapy company through strategic acquisitions, licensing arrangements, and pipeline expansion initiatives centered on genetic medicine.